Death Caused by Disseminated Herpes Zoster in a Patient with Multiple Myeloma: A Case Report and Literature Review
Yang Bo,Xiaojing Zhong,Yanping Xiang,Qingjun Ren,Pingsheng Hao
DOI: https://doi.org/10.2147/ccid.s464039
2024-04-27
Clinical Cosmetic and Investigational Dermatology
Abstract:Yang Bo, Xiaojing Zhong, Yanping Xiang, Qingjun Ren, Pingsheng Hao Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China Correspondence: Pingsheng Hao, Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, 39 Shi-Er-Qiao Road, Jinniu District, Chengdu, Sichuan, 610072, People's Republic of China, Tel +86138 8196 5024, Fax +86-28-87732407, Email We report a fatal case of disseminated herpes zoster in a patient with multiple myeloma, illustrating the severe risks immunocompromised individuals face from viral infections. By combining a detailed case report with an extensive literature review, the paper seeks to shed light on the underlying susceptibility factors for varicella-zoster virus infection in multiple myeloma patients. We further evaluate effective prophylactic protocols for herpes zoster, aiming to equip clinicians with improved therapeutic strategies. The case underscores the critical need for vigilant clinical assessments and tailored patient management to mitigate infection risks and enhance patient outcomes. Keywords: multiple myeloma, disseminated herpes zoster, antiviral prophylaxis, immunodeficiency Herpes zoster (HZ) is an acute infectious skin disease caused by reactivation of varicella zoster virus (VZV) latent in the ganglia. Lesions of HZ are usually confined to a single dermatomal area, and non-adjacent HZ involving two or more dermatomes is rare. Disseminated herpes zoster (DHZ) is termed when more than two contiguous zones are affected or when more than 20 or more varicella-like rashes or visceral involvement are observed outside the initial zone. 1 Multiple myeloma (MM) is a malignant disease of the haematological system, in which the clonal proliferation of plasma cells in the bone marrow produces large amounts of aberrant monoclonal immunoglobulins, which inhibit normal immunoglobulin synthesis, leading to reduced immune function, and MM cells act on the bone marrow microenvironment, which further contributes to the patient's immunocompetence, leading to herpes zoster. 2,3 In individuals with MM, the sustained use of antineoplastic agents, including immunosuppressives and proteasome inhibitors, leads to the suppression of both humoral and cellular immune responses. This immunosuppression significantly increases the risk of herpes zoster, with an incidence rate that is 14.8 times higher than that of the general population. 4 Here, we report a case of multiple myeloma patient complicated with disseminated herpes zoster resulting in death. We hope to review this case to analyse the susceptibility factors for VZV infection in MM patients, as well as to summarise effective prophylactic protocols for herpes zoster in patients with multiple myeloma through an extensive review of the literature, with a view to providing clinicians with better therapeutic strategies. A 58-year-old Chinese male presented to the hospital on 23 May 2023 with a week-long history of erythematous blisters accompanied by pruritus and pain localized to the right inner thigh and buttock. Initially characterized by clustered papules and vesicles, the lesions evolved rapidly, and some of the blisters broke and oozed. Within a day post-admission, a generalized blister-like rash ensued, marked by widespread itching. The patient was in poor physical condition and suffered from hypertension for 10 years. On 25 October 2021, he was hospitalized in other hospital because of oedema of both lower limbs and foamy urine. The biochemical profile was revealing, with albumin at 23.1g/L, globulin at 16.8g/L, creatinine at 190 umol/L, an estimated glomerular filtration rate (eGFR) of 33.21 mL/min/1.73m2, triglycerides at 3.03 mmol/L, and a concerning 24-hour urine protein excretion of 4.54g, pointing towards nephrotic syndrome and stage 3 chronic kidney disease. Further investigations, including a renal biopsy conducted on October 28, 2021, revealed amyloid renal degeneration. A subsequent bone marrow biopsy on November 3, 2021, confirmed the presence of multiple myeloma. The patient embarked on a rigorous therapeutic regimen, encompassing bortezomib (2.5mg weekly), dexamethasone (15mg twice weekly), and cyclophosphamide (four tablets twice weekly) for seven cycles, alongside seven sessions of bedside dialysis, culminating in a stem cell transplantation in September 2022. However, the post-chemotherapy trajectory was fraught with myelosuppression, manifesting as anemia, thrombocytopenia, and granulocytopenia, and marred by recurrent hospital admissions due to pulmonary infections. These clinical episodes were meticulously cataloged as severe pneumonia, hypoxemia, stage 5 chronic kidney disease, hemodialysis reliance, compounded by the underlying specters of multiple myeloma, renal amyloi -Abstract Truncated-
dermatology